Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Therapeutic
- Disease
- Pharmaceuticals
- Diagnostic
- Cancer
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2379
License Grant
The Company hereby assigns to the Licensee all its rights and obligations under the Amended and Restated License Agreement insofar as such rights and obligations pertain to the Territory. The License holds the rights to market Levulan® PDT in Canada.
License Property
The Levulan® brand of aminolevulinic acid HCl, or ALA, with light, for use, or potential use, in a broad range of medical conditions. When we use Levulan® and follow it with exposure to light to treat a medical condition, it is known as Levulan® photodynamic therapy, or Levulan® PDT. When we use Levulan® and follow it with exposure to light to detect medical conditions it is known as Levulan® photodetection, or Levulan(R) PD.
Field of Use
The rights granted apply to a broad range of medical conditions.
IPSCIO Record ID: 237271
License Grant
With this termination agreement, Licensee shall be free to develop and commercialize Products and the Method in the Territory.
The Canadian Licensor will return or transfer to Licensee all data, information and materials including, without limitation, all pre-clinical and clinical study data and results, reports, records, market research, Confidential Information and all regulatory filings (e.g., all CTAs, Registration Applications and Registrations) (collectively, the Materials), together with all know-how, including Licensors Know-How, pertaining to the development and commercialization of Products and the Method as well as the Licensees Product,
To the extent required for Licensee to access Materials in the possession of third party contractors and collaboration partners engaged by Licensor or its Affiliates to perform services on its or their behalf including, without limitation, to conduct preclinical or clinical studies on Products and the Method as well as the Licensee Product; or market research on the Licensee Product, Licensor agrees to grant permission under any applicable agreement for such third parties to give access to Licensee Product in their possession.
Licensor and its Affiliates grant to Licensee an exclusive, irrevocable, right and license under the Licensor Intellectual Property to develop, make, have made, use, offer to sell, sell and have sold Products, the Method and the Licensee Product for all indications worldwide. The foregoing license shall include the right to grant sublicenses.
For the Protection of Proprietary Information. In addition to the foregoing, any Materials and know-how, including Licensor Know-How, pertaining to the development and commercialization of Products, the Method and Licensee Product, developed by Licensor, its Affiliates and/or their third party contractors or collaboration partners during the term of the Assignment (collectively, Proprietary Information) shall be deemed to be the confidential and proprietary information of Licensee as the disclosing party.
License Property
Licensee Product shall mean collectively Levulan® 20% topical solution; and Licensees proprietary, disposable applicator being commercialized under the trademark Kerastick®, for the application of Levulan 20% topical solution.
Levulan®' shall mean Licensees brand of the chemical compound 5 – aminolevulinic acid HCI.
Field of Use
The licensed product Levulan(R) brand of aminolevulinic acid HCl, or ALA, with light, is for use in a broad range of medical conditions. When Levulan(R) is used and followed with exposure to light to treat a medical condition, it is known as Levulan(R) photodynamic therapy, or Levulan(R) PDT. When Levulan(R) is used and followed with exposure to light to detect medical conditions it is known as Levulan(R) photodetection, or Levulan(R) PD.
Levulan is indicated for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
IPSCIO Record ID: 1182
License Grant
The Sublicense assigned to the Company its rights and obligations under the Parteq License insofar as they relate to Canada.
License Property
Parteq patent rights refer to brand of 5-aminolevulinic acid (ALA). Methods of Diagnosis and/or Treatment Using Photodynamic Therapy Compositions for Detection or Treatment-U>U.S. Patent 5,079,262; 5,211,938; 5,234,940; 5,422,093.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 1634
License Grant
The Company has been granted an exclusive worldwide license (with a right to sublicense) by Canadian Licensee to make, have made, use and sell products which are precursors of PpIX, including ALA, under Licensor patent rights; brand of 5-aminolevulinic acid (ALA); method for detecting and/or treating primary or secondary malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium in which a precursor to protoporphyrin IX, including 5-amino levulinic acid (ALA).
License Property
Methods of Diagnosis and/or Treatment Using Photodynamic Therapy Compositions for Detection or Treatment-U.S. Patent 5,079,262; 5,211,938; 5,234,940; 5,422,093.
Field of Use
The rights granted apply to the skin.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
